Free Newsletter
GSK to report organization grants
Full disclosure: Getting pharma to fess up on its payments to doctors is only part of the drive for that sort of data. Some have been pushing drugmakers to tell how much they're giving to health-related organizations, too. Now, GlaxoSmithKline has announced that it will report its grants to U.S. hospitals, CME companies, patient advocacy groups, professional associations and the like. The reports will come quarterly beginning in February 2009.
GSK's move comes at a time when payments of all sorts are coming under increased scrutiny. Everything from academic research support to doctor speaking fees is coming under the microscope, not only in the media, but in Congressional hearings and in some professional-association research. So drugmakers are taking steps--slowly but surely--toward increased transparency. Criticism of industry-funded CME prompted Pfizer, for instance, to stop paying for any courses offered by for-profit CME companies. Look for more pharma firms to make similar pledges as the year goes on.
--see GlaxoSmithKline's release
--Vote: Should drug and medical device makers be required to report payments made to doctors?
Related Articles:
Americans want doc payments disclosed
Harvard officials to probe psychiatrists' drug payments
Med schools don't police pharma gifts, report says
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: